Next Article in Journal
The Lipid Paradox as a Metabolic Checkpoint and Its Therapeutic Significance in Ameliorating the Associated Cardiovascular Risks in Rheumatoid Arthritis Patients
Next Article in Special Issue
Microphthalmia-Associated Transcription Factor-Dependent Melanoma Cell Adhesion Molecule Activation Promotes Peritoneal Metastasis of Ovarian Cancer
Previous Article in Journal
Are There Epigenetic Oxytocin-Mediated Effects on the Mother and Infant during Physiological Childbirth?
Previous Article in Special Issue
LDOC1 as Negative Prognostic Marker for Vulvar Cancer Patients
Open AccessReview

Molecular Features and Clinical Management of Hereditary Gynecological Cancers

by 1 and 2,*
1
Center for Medical Genetics, Keio Cancer Center, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan
2
Department of Clinical Genomic Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(24), 9504; https://doi.org/10.3390/ijms21249504
Received: 19 November 2020 / Revised: 8 December 2020 / Accepted: 11 December 2020 / Published: 14 December 2020
Hereditary gynecological cancers are caused by several inherited genes. Tumors that arise in the female reproductive system, such as ovaries and the uterus, overlap with hereditary cancers. Several hereditary cancer-related genes are important because they might lead to therapeutic targets. Treatment of hereditary cancers should be updated in line with the advent of various new methods of evaluation. Next-generation sequencing has led to rapid, economical genetic analyses that have prompted a concomitant and significant paradigm shift with respect to hereditary cancers. Molecular tumor profiling is an epochal method for determining therapeutic targets. Clinical treatment strategies are now being designed based on biomarkers based on tumor profiling. Furthermore, the National Comprehensive Cancer Network (NCCN) guidelines significantly changed the genetic testing process in 2020 to initially consider multi-gene panel (MGP) evaluation. Here, we reviewed the molecular features and clinical management of hereditary gynecological malignancies, such as hereditary breast and ovarian cancer (HBOC), and Lynch, Li–Fraumeni, Cowden, and Peutz–Jeghers syndromes. We also reviewed cancer-susceptible genes revealed by MGP tests. View Full-Text
Keywords: hereditary gynecological cancer; multi-gene testing; tumor profiling; hereditary breast and ovarian cancer (HBOC); Lynch; Li–Fraumeni; Cowden; Peutz–Jeghers; syndrome hereditary gynecological cancer; multi-gene testing; tumor profiling; hereditary breast and ovarian cancer (HBOC); Lynch; Li–Fraumeni; Cowden; Peutz–Jeghers; syndrome
Show Figures

Figure 1

MDPI and ACS Style

Ueki, A.; Hirasawa, A. Molecular Features and Clinical Management of Hereditary Gynecological Cancers. Int. J. Mol. Sci. 2020, 21, 9504. https://doi.org/10.3390/ijms21249504

AMA Style

Ueki A, Hirasawa A. Molecular Features and Clinical Management of Hereditary Gynecological Cancers. International Journal of Molecular Sciences. 2020; 21(24):9504. https://doi.org/10.3390/ijms21249504

Chicago/Turabian Style

Ueki, Arisa; Hirasawa, Akira. 2020. "Molecular Features and Clinical Management of Hereditary Gynecological Cancers" Int. J. Mol. Sci. 21, no. 24: 9504. https://doi.org/10.3390/ijms21249504

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop